IMMUTEP LIMITED - AMER
2.0300
08-October-24 09:26:50
15 minutes delayed
Stocks
-0.0200
-0.98%
Today's range
2.0200 - 2.0500
ISIN
N/A
Source
NASDAQ
-
29 Oct 2021 07:00:00 By Nasdaq GlobeNewswire
-
Immutep Quarterly Activities Report & Appendix 4C
28 Oct 2021 07:00:02 By Nasdaq GlobeNewswire
-
Immutep to Present Phase II TACTI-002 Data at SITC 2021
01 Oct 2021 07:00:02 By Nasdaq GlobeNewswire
-
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
29 Sep 2021 07:00:00 By Nasdaq GlobeNewswire
-
Immutep to Present at Healthcare Investor Conferences
28 Sep 2021 07:00:01 By Nasdaq GlobeNewswire
-
21 Sep 2021 07:38:03 By Nasdaq GlobeNewswire
-
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
01 Sep 2021 07:00:00 By Nasdaq GlobeNewswire
-
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
31 Aug 2021 07:00:01 By Nasdaq GlobeNewswire
-
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
27 Aug 2021 07:00:00 By Nasdaq GlobeNewswire
-
05 Aug 2021 07:00:02 By Nasdaq GlobeNewswire
-
Immutep Quarterly Activities Report
13 Jul 2021 07:00:03 By Nasdaq GlobeNewswire
-
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
06 Jul 2021 07:00:01 By Nasdaq GlobeNewswire
-
21 Jun 2021 07:00:00 By Nasdaq GlobeNewswire
-
21 Jun 2021 07:00:00 By Nasdaq GlobeNewswire
-
Immutep Reveals a New Anti-LAG-3 Research Program
08 Jun 2021 07:00:01 By Nasdaq GlobeNewswire
-
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
04 Jun 2021 07:00:01 By Nasdaq GlobeNewswire
-
04 Jun 2021 07:00:00 By Nasdaq GlobeNewswire
-
02 Jun 2021 07:00:02 By Nasdaq GlobeNewswire
-
Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti
01 Jun 2021 07:00:01 By Nasdaq GlobeNewswire
-
Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination
26 May 2021 07:00:01 By Nasdaq GlobeNewswire